Agouron Acquires New Anti-HIV Drug from Shionogi [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

Agouron Acquires New Anti-HIV Drug From Shionogi
June 29, 1998
Page 2
engineered to inactivate proteins that play key roles in cancer, AIDS, and other serious diseases.
Shionogi & Co., Ltd. is one of Japan's largest research based pharmaceutical companies
with principle businesses in pharmaceuticals, diagnostics and clinical testing services,
agrochemical and animal health products and industrial chemicals.
This press release may contain forward-looking statements or predictions. These
statements represent our judgment as of this date and are subject to risks and uncertainties
(including those associated with regulatory approvals and the impact of competitive products) that
could cause the actual results to differ materially. Important factors concerning these risks are
discussed in our Form 10-K for the fiscal year ended June 30, 1997 currently on file with the
Securities and Exchange Commission. Agouron undertakes no obligation to publicly release the
result of any revisions to such forward-looking statements which may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For more information on Agouron, you may visit the Agouron Web Site at
http://www.agouron.com.
Viramune~ is a registered trademark of Roxane Laboratories, Inc.
Rescriptor~ is a registered trademark of the Pharmacia & UpJohn Company.
SustivaTM is a trademark of DuPont Pharmaceuticals, Inc.